Component

S-allyl-L-cysteine sulfoxide, stereoisomer unspecified

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. SAC sulfoxide was identified among metabolites after SAC administration to rats and dogs.

    Experimental context and source evidence
    acting_entity
    s-allylcysteine
    dose
    Rats 5 mg/kg; dogs 2 mg/kg
    duration
    Single administration
    evidence_access
    Primary abstract
    experimental_comparison
    Purified SAC or N-acetyl-SAC; corresponding pharmacokinetic comparisons
    experimental_model
    Oral/i.v. pharmacokinetics; liver and kidney S9 experiments
    interpretation_status
    Source-derived research curation; not independent primary verification
    limitations
    Sulfoxide stereochemistry and responsible enzyme were not resolved in the accessed abstract.
    nutrient_topic
    S-allylcysteine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · S-allyl-L-cysteine / SAC
    organism
    Rat and dog
    plain_language
    Oxidation creates another chemically distinct species.
    primary_references
    [25681129] Metabolism, excretion, and pharmacokinetics of S-allyl-L-cysteine in rats and dogs. · 2015 · https://pubmed.ncbi.nlm.nih.gov/25681129/ · DOI 10.1124/dmd.115.063230
    route
    Oral or intravenous; S9 incubation separately
    tissue_or_cell_type
    Oral/i.v. pharmacokinetics; liver and kidney S9 experiments

    S-allylcysteine: sulfur signaling, redox responses and cross-nutrient mechanisms (2026-09-20) · lines 32–39

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Oral/i.v. pharmacokinetics; liver and kidney S9 experiments · source_derived_draft · unverified_draft

    ## s-allylcysteine-s-oxidation Oxidation creates another chemically distinct species. SAC sulfoxide was identified among metabolites after SAC administration to rats and dogs. Model: Oral/i.v. pharmacokinetics; liver and kidney S9 experiments Limitations: Sulfoxide stereochemistry and responsible enzyme were not resolved in the accessed abstract. Evidence access: Primary abstract [25681129] Metabolism, excretion, and pharmacokinetics of S-allyl-L-cysteine in rats and dogs. · 2015 · https://pubmed.ncbi.nlm.nih.gov/25681129/ · DOI 10.1124/dmd.115.063230 Structured context: {"organism": "Rat and dog", "tissue_or_cell_type": "Oral/i.v. pharmacokinetics; liver and kidney S9 experiments", "dose": "Rats 5 mg/kg; dogs 2 mg/kg", "duration": "Single administration", "route": "Oral or intravenous; S9 incubation separately", "experimental_comparison": "Purified SAC or N-acetyl-SAC; corresponding pharmacokinetic comparisons", "acting_entity": "s-allylcysteine", "interpretation_status": "Source-derived research curation; not independent primary verification"}
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards